Octapharma USA has presented interim results from clinical trials looking at the potential of Nuwiq (antihemophilic factor [recombinant]) to address unmet medical need in hemophilia.
Octapharma is trialling Nuwiq to see if it can address two major challenges for hemophilia patients: the development of inhibitors, and the need for frequent venous access for injections.
The results were presented at a recent symposium of the Hemostasis and Thrombosis Research Society. Final data are expected in 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze